Telephone
(+49)231 755-2339

M. Sc. Laura David

INVITE GmbH

CHEMPARK, Geb. W 32

Kaiser-Wilhelm-Allee 50

51373 Leverkusen

Room G2-R3.20

Curriculum Vitae

Field of Research

The market for monoclonal antibodies (mAb) changes drastically due to different reasons. The trend to a more personalized medicine and niche products, an increased cost pressure and large market growth rates make production adjustments unavoidable. Therefore, the existing batch-wise operated large-scale stainless steel plants are questioned. Continuous processing of mAb within single use plants seems to be a promising alternative to meet the future demands.

Within the continuous manufacturing of biopharmaceutical products, especially mAb, the continuous viral clearance plays an important role. In order to ensure the product safety, already applied fed-batch strategies have to be adapted into the continuous process mode.

Oral presentations:

• L. David, B. Maiser, P. Schwan, M. Lobedann, L. M. Waldschmidt, M. Bayer, M. Lasse, H. Ruppach, G. Schembecker
  Continuous Low pH Viral Inactivation for mAb Production Processes
  2018 PDA Virus Forum, Florence, Italy (2018)

• L. David, B. Maiser, P. Schwan, M. Lobedann, L. M. Waldschmidt, M. Bayer, M. Lasse, H. Ruppach, G. Schembecker
  Continuous Low pH Viral Inactivation for mAb Production Processes
  Bioprocess International European Summit, Amsterdam, Netherlands (2018)
  
  
  
• L. David, S. Klutz, M. Lobedann, B. Maiser, J. Niklas, P. Schwan, G. Schembecker
  Continuous Processing of Biopharmaceuticals: Virus Clearance
  2017 PDA Modern Biopharmaceutical Processing Conference, Singapore (2017)
  
  
  
• L. David, B. Maiser, M. Lobedann, P. Schwan, M. Fröhlich, H. Ruppach, L. M. Waldschmidt, G. Schembecker
  Low pH viral inactivation for continuous, biopharmaceutical processes
  Charles River 2017 Viral Safety and Viral Clearance Summit, San Mateo, CA, USA ( 2017)
  
  
  
• L. Holtmann, S. Klutz, B. Maiser, J. Niklas, P. Schwan, M. Lobedann, G. Schembecker
  Continuous viral clearance for the production of mAbs
  Virus & TSE Safety Forum, Dubrovnik, Croatia (2017)
  
  
  
• L. Holtmann, S. Klutz, M. Lobedann, B. Maiser, J. Niklas, G. Schembecker
  Continuous and disposable production of mAb
  Continuously improving bioprocesses workshop, Pall Life Sciences, Tokyo, Japan (2016)

• L. Holtmann, S. Klutz, M. Lobedann, B. Maiser, J. Niklas, G. Schembecker
  Continuous processing of mAb - achievements, benefits and remaining challenges
  Lilly continuous processing workshop, Eli Lilly and Company, Indianapolis, USA  (2016)
  
  

• L. Holtmann, S. Klutz, M. Lobedann, B. Maiser, J. Niklas, G. Schembecker
  Viral clearance for continuous processes
  8th Workshop on Monoclonal Antibodies, Berlin, Germany (2015) 

Poster presentations

• L. David, J. Niklas, B. Budde, M. Lobedann, P. Schwan, G. Schembecker
  Continuous Viral Filtration for mAb Production Processes
  2018 PDA Virus Forum, Florence, Italy (2018)

• L. David, J. Niklas, B. Budde, M. Lobedann, P. Schwan, G. Schembecker
  Continuous Viral Filtration for mAb Production Processes
  Bioprocess International European Summit, Amsterdam, Netherlands (2018)

• L. David, M. Lobedann, J. Magnus, G. Schembecker
  Possibilities and challenges for continuous viral clearance within disposable equipment
  Charles River 2017 Viral Safety and Viral Clearance Summit, San Mateo, CA, USA ( 2017)
  
  

• L. Holtmann, J. Magnus, M. Lobedann, G. Schembecker
  Disposables for continuous viral clearance for mAb production
  Virus & TSE Safety Forum, Dubrovnik, Croatia (2017)

• L. Holtmann, M. Lobedann, J. Magnus, G. Schembecker
  Continuously operated production of mAb – viral clearance strategies
  Dechema Himmelfahrtstagung, Koblenz, Germany (2016)
  
  

• L. Holtmann, S. Klutz, J. Niklas, B. Maiser, M. Lobedann, G. Schembecker
  Viral clearance for continuous processes
  Virus/TSE Safety Forum, Lisbon, Portugal (2015)
  
  
  

Paper

• L.Holtmann, S.Klutz, M.Lobedann, G.Schembecker
  mAbs: hybrid style
  The Medicine Maker; 0816-304; September 2016
  
  

• L. Holtmann, M. Lobedann, J. Magnus, G. Schembecker
  Disposables for continuous viral clearance for the production of monoclonal antibodies
  European Pharmaceutical Review 21(2)  2016 22-27
  
  

• Klutz, S., Holtmann, L., Lobedann, M., Schembecker, G.
  Cost evaluation of antibody production processes in different operation modes
  Chemical Engineering Science 141 (2016), 63–74
  
  
  

Patents

• B. Maiser, P. Schwan, L. Holtmann, M. Lobedann
  Validation of continuous viral clearance
  EP3141611A2, 15.3.2017